Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Nov 8, 2005

Third quarter 2005: Adjusted EPS up 27.4%, net sales up 11.0% on a comparable basis - First 9 months of 2005: Adjusted EPS up 26.6%, net sales up 11.0% on a comparable basis
Nov 7, 2005

New data show long-term (52 week) use of ALVESCO® (ciclesonide) had a low incidence of oropharyngeal side effects in patients with mild-to-moderate asthma
Oct 20, 2005

EXUBERA® inhaled insulin improves blood sugar levels in adults with type 2 diabetes better than diabetes pills alone
Oct 7, 2005

AMBIEN CR™ now available in the US
Sep 29, 2005

Hearing date set on motion for preliminary injunction in ALLEGRA® (fexofenadine hcl) patent infringement case
Sep 29, 2005

Sanofi-aventis provides relief to hurricane victims
Sep 20, 2005

FDA accepts filed pre-market approval supplement to expand the indication for HYALGAN® (sodium hyaluronate) to include shoulder pain due to osteoarthritis
Sep 15, 2005

INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER
Sep 14, 2005

Study Finds Alvesco® (ciclesonide) Did Not Affect HPA-Axis Function in Patients with Moderate-to-Severe Persistent Asthma
Sep 12, 2005

Sanofi-aventis Group enters agreement with Prasco Laboratories to market generic versions of ALLEGRA® (fexofenadine HCl)

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.